Daily Cardiology Research Analysis
Analyzed 203 papers and selected 3 impactful papers.
Summary
Three high-impact studies advance cardiology: (1) multi-omic human research dissects how distinct 4q25 AF risk variants differentially disrupt atrial calcium handling and left atrial function; (2) mechanistic work uncovers a urea cycle–to–TCA fumarate axis that restrains fibroblast ATP production and limits post-MI fibrosis; and (3) a randomized trial shows renin–angiotensin system inhibition after TAVR augments reverse LV remodeling. Together, they point to genotype-tailored AF strategies, metabolic anti-fibrotic targets, and optimization of post-TAVR medical therapy.
Research Themes
- Genotype-specific mechanisms and precision targets in atrial fibrillation
- Metabolic reprogramming of cardiac fibroblasts as anti-fibrotic therapy
- Optimizing post-TAVR medical therapy to enhance reverse remodeling
Selected Articles
1. Multiple 4q25 risk variants impair calcium homeostasis and compromise left atrial function.
Across population-scale genetics, human atrial tissue, and ex vivo electrophysiology, distinct 4q25 AF risk variants map to different calcium-handling defects and left atrial phenotypes. rs1448818 was linked to reduced ICaL, whereas rs2200733/rs10033464 increased spontaneous calcium release signatures and left atrial dysfunction. The work supports genotype-tailored strategies to restore ICaL (rs1448818) or suppress spontaneous Ca release (rs2200733/rs10033464).
Impact: This is a rigorous, multi-system human study that mechanistically links common AF risk variants to distinct calcium-handling defects and atrial remodeling, moving beyond association to actionable biology.
Clinical Implications: While not practice-changing yet, the data prioritize genotype-targeted strategies: augment ICaL in rs1448818 carriers and curb spontaneous Ca release in rs2200733/rs10033464, informing precision AF prevention/therapy and trial design.
Key Findings
- In UK Biobank (n=391,008), all three 4q25 risk alleles increased 10-year incident AF in a dose-dependent manner; genetic and clinical risk were additive for rs2200733.
- rs2200733 carriers had higher PITX2C mRNA expression in human atrial tissue.
- In human atrial myocytes (n=66), ICaL was reduced only with rs1448818, whereas ITI frequency increased with rs2200733 or rs10033464; rs10033464 raised SR Ca load, and rs2200733 increased RyR2 Ser2808 phosphorylation and beat-to-beat alternans.
- Cardiac MRI (n=39,391 without AF) showed increased LA volumes and reduced active LA ejection fraction with rs1448818 or rs2200733, but preserved function with rs10033464.
Methodological Strengths
- Integration of very large-scale genetics with human atrial tissue expression, ex vivo patch-clamp, and population cardiac MRI
- Convergent mechanistic readouts (ICaL, ITI, SR Ca load, RyR2 phosphorylation) supporting causal pathways
Limitations
- Observational genetic associations cannot establish intervention efficacy; residual confounding and ancestry effects possible
- Electrophysiology based on a moderate number of human cells; no genotype-stratified therapeutic trial yet
Future Directions: Prospective, genotype-stratified interventions to restore ICaL (e.g., Ca channel modulation) or suppress spontaneous Ca release (e.g., RyR2 leak) and assess AF burden and atrial function.
AIMS: Single-nucleotide polymorphisms (SNPs) from distinct linkage blocks in the chromosomal region 4q25 (rs1448818, rs2200733 and rs10033464) are associated with increased risk of atrial fibrillation (AF), but their impact on cardiomyocyte and atrial function remain elusive. Here, we tested the hypothesis that these SNPs have differential effects on calcium homeostasis that may afford SNP-specific targets and help explain their impact on atrial function. METHODS AND RESULTS: Analysis of 391,008 individuals from the UK biobank revealed that the three risk-alleles increased incident AF during 10-year period in a dose-dependent manner, and that genetic and clinical risk was additive for the rs2200733 risk variant. Analyses of PITX2C mRNA expression in human atrial tissue showed that the rs2200733 risk variant increased PITX2C expression. Moreover, patch-clamp analyses in human atrial myocytes from 66 patients without AF revealed that L-type calcium current (ICaL) was significantly reduced in carriers of the rs1448818 risk allele only. In contrast, the transient inward current (ITI) frequency was significantly higher in carriers of rs2200733 or rs10033464 risk alleles only. This concurred with increased sarcoplasmic reticulum calcium load in those with the rs10033464 risk allele, while myocytes with the rs2200733 risk allele had increased ryanodine receptor 2 phosphorylation at Ser2808 (n=119) and displayed pronounced beat-to-beat alternation when paced. Finally, linear regression analyses of cardiac MRI data from 39,391 individuals in the UK biobank without AF showed that beta-values for minimal and maximal left atrial volume were increased and active ejection fraction (LAAEF) decreased in carriers of rs1448818 or rs2200733 risk alleles but preserved in individuals with the rs10033464 risk allele. CONCLUSIONS: Distinct 4q25 risk SNPs produce differential alterations in intracellular calcium homeostasis that may help understand their impact on atrial function or rhythm. Moreover, the findings suggest that genotype-tailored strategies aiming to restore ICaL density may be effective for rs1448818, while attenuation of spontaneous calcium release may be suitable for rs2200733 or rs10033464 variants.
2. Urea cycle fumarate limits fibrosis post-MI by reducing fibroblast mitochondrial ATP production.
This mechanistic study reveals a urea cycle–to–TCA fumarate axis (NAcGlu→ASL→fumarate) that restrains fibroblast ATP generation and limits post-MI fibrosis. Exogenous NAcGlu or fumarate improved function and reduced scar, whereas fibroblast-specific ASL deletion abrogated benefit, highlighting a metabolite/enzyme targetable pathway.
Impact: It uncovers a previously unappreciated metabolic bridge from the urea cycle to TCA flux that governs fibroblast activation, offering precise, testable anti-fibrotic targets (metabolites and ASL) after MI.
Clinical Implications: Although preclinical, targeting the NAcGlu/ASL/fumarate axis suggests metabolite supplementation or enzyme modulation strategies to attenuate adverse remodeling post-MI, and may inform combination approaches with SGLT2 inhibitors.
Key Findings
- Integrated metabolomics/flux profiling identified a NAcGlu→ASL→fumarate pathway linking urea cycle to TCA in ischemic fibroblasts.
- SGLT2 inhibition conferred anti-fibrotic benefit post-MI; exogenous NAcGlu or fumarate improved cardiac function and reduced fibrosis.
- Fibroblast-specific ASL deletion impaired cardiac performance and nullified NAcGlu benefit, indicating pathway necessity.
- Fumarate accumulation under stress reduced fibroblast TCA flux and ATP production, limiting myofibroblast trans-differentiation.
Methodological Strengths
- Multi-omics integration with metabolic flux analysis and in vivo validation post-MI
- Genetic perturbation (fibroblast-specific ASL deletion) establishing pathway necessity
Limitations
- Preclinical animal and cellular models without human clinical validation
- Long-term safety and translational dosing of metabolite/enzyme targeting remain unknown
Future Directions: Validate the NAcGlu/ASL/fumarate axis in human cardiac tissue, define therapeutic windows/dosing, and test metabolite or ASL-modulating agents in large-animal models and early-phase trials.
AIMS: Cardiac fibrosis, a common pathological outcome of various heart diseases including myocardial infarction (MI), is primarily driven by the activation and trans-differentiation of cardiac fibroblasts which demand substantial ATP for energy. Although sodium-glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin (DAPA) have been shown to improve outcomes in heart failure, their direct impact on cardiac fibrosis, particularly through the modulation of fibroblast energy metabolism remains unexplored. METHODS AND RESULTS: We employed an integrated strategy combining metabolomics and metabolic flux analysis to investigate metabolic reprogramming in cardiac fibroblasts under ischaemic conditions. Our findings confirmed that treatment with an SGLT2 inhibitor confers anti-fibrotic benefits post-MI. Multi-omics analysis identified a key metabolic pathway modulated in fibroblasts from SGLT2 inhibitor-treated mice under ischaemia: the conversion of N-acetyl-glutamate (NAcGlu) to fumarate, catalysed by argininosuccinate lyase (ASL). This pathway serves as a metabolic bridge linking the urea cycle to the tricarboxylic acid (TCA) cycle. Exogenous supplementation with either NAcGlu or fumarate significantly improved cardiac function and reduced fibrosis after MI. In contrast, targeted deletion of ASL in activated cardiac fibroblasts impaired cardiac performance, even with NAcGlu supplementation. Mechanistically, we found that fumarate accumulation under stress presses the TCA cycle in cardiac fibroblasts, resulting in reduced ATP production. CONCLUSIONS: These findings identify the NAcGlu/ASL/fumarate axis as an important regulator of fibroblast metabolism and trans-differentiation during ischaemic stress. Our data are consistent with a model in which targeting key metabolites (NAcGlu, fumarate) or enzymes (ASL) in the urea cycle pathway of cardiac fibroblasts may point to a potential therapeutic strategy to combat adverse cardiac fibrosis following MI.
3. Effect of renin-angiotensin system inhibition on left ventricular mass regression after transcatheter aortic valve replacement: a randomised controlled trial.
In a multicentre randomized, open-label, blinded-endpoint trial after successful TAVR, RAS inhibition achieved greater 12‑month LV mass regression and volume reduction versus standard care, with modest functional improvement but no significant LVEF or NT‑proBNP changes. Findings support RASi to augment reverse remodeling post-TAVR.
Impact: This is a randomized, blinded-endpoint trial addressing a modifiable, clinically relevant target—post-TAVR myocardial remodeling—showing structural benefits with readily available therapies.
Clinical Implications: RAS inhibitors (ACEi/ARB/ARNI) may be considered post-TAVR to enhance reverse remodeling in patients with LVEF ≥40%, pending larger outcomes trials to determine effects on hard endpoints.
Key Findings
- RAS inhibition produced greater 12-month LV mass index reduction vs control (adjusted mean difference −12.77 g/m²; p=0.036).
- LV end-diastolic and end-systolic volumes decreased more with RASi; NYHA class improved modestly.
- No significant between-group differences in LVEF or NT-proBNP at 12 months.
Methodological Strengths
- Randomized, multicentre design with blinded endpoint assessment
- Registered trial with prespecified structural endpoints
Limitations
- Open-label design and modest sample size; surrogate endpoints rather than hard clinical outcomes
- Follow-up limited to 12 months; medication class heterogeneity within RAS inhibition
Future Directions: Larger randomized trials powered for clinical outcomes (mortality, HF hospitalization) to test whether structural benefits translate into improved prognosis and to refine class-specific RASi strategies post-TAVR.
BACKGROUND: Residual left ventricular (LV) hypertrophy and incomplete reverse remodelling after transcatheter aortic valve replacement (TAVR) are associated with adverse outcomes. Whether renin-angiotensin system inhibitors (RASi) promote reverse remodelling in patients with heart failure and LV ejection fraction (LVEF) ≥40% following TAVR remains uncertain. METHODS: In this multicentre, prospective, randomised, open-label, blinded-endpoint trial, patients aged ≥60 years with symptomatic severe aortic stenosis, LVEF ≥40% and successful TAVR were randomly assigned (1:1) to standard care alone or standard care plus RASi (ACE inhibitor, angiotensin II receptor blocker or angiotensin receptor-neprilysin inhibitor). The primary endpoint was change in LV mass index (LVMI) at 12 months. Secondary endpoints included changes in LV volumes, LVEF, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and functional status. RESULTS: A total of 200 patients were randomised; 194 were included in the modified intention-to-treat analysis (RASi n=95; control n=99). At 12 months, RASi therapy was associated with a greater reduction in LVMI compared with control (adjusted mean difference -12.77 g/m², 95% CI -24.73 to -0.81; p=0.036). Consistent improvements were observed in LV end-diastolic and end-systolic volumes. Functional status (New York Heart Association class) improved modestly in the RASi group. No significant differences were observed in LVEF or NT-proBNP. CONCLUSION: In patients with heart failure and LVEF ≥40% following TAVR, RAS inhibition led to enhanced reverse LV remodelling over 12 months, reflected by greater regression of LV mass and volumes. These findings support the potential role for RASi in modifying post-TAVR myocardial remodelling, although larger trials are required to determine whether these structural benefits translate into improved clinical outcomes. TRIAL REGISTRATION NUMBER: ChiCTR2100042266.